NASDAQ, EDAP - Edap Tms Sa ADR

We develop and market the Ablatherm?, an advanced choice for High Intensity  Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment  is shown to be a minimally invasive and effective treatment option for localized  prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is  generally recommended for patients with localized prostate cancer (stages T1-T2)  who are not candidates for surgery or who prefer an alternative option. It is  also used for patients who failed a radiotherapy treatment. In addition, we are  developing HIFU technology for the treatment of certain other types of tumors.  We also produce and commercialize medical equipment for treatment of urinary  tract stones using Extra-corporeal Shockwave Lithotripsy (?ESWL?).  ...

Sector:	Health Care
Industry:	Biotechnology: Electromedical & Electrotherapeutic Apparatus
P/E Ratio:	N/A
PEG Ratio:	86.7
EPS:	N/A
DivYield:	N/A
PtB:	1.7245
PtS:	2
EBITDA:	270.4K
Shares:	37.39M
Market Cap:	46.74M
52wk range:	1.26 - 4.93

216.73.216.229
United States